Work

Phase II Exploratory Study of Neoadjuvant Disitamab Vedotin and Penpulimab in HER2-low Stage II-III Breast Cancer (NeoPanDa04)

Year: 2025

Type: preprint

Study design: Clinical Trial

Source: Research Square

DOI: 10.21203/rs.3.rs-7869437/v1

Authors: Ting Luo, Xiaoxiao Liu, Yuting Song, Lei Liu, Aaron Qi Zhang, Xin Xie, Bing Wei, Ping He, Chunying Zhuang, Juanjuan Li, Xi Yan, Tinglun Tian, Xiaorong Zhong, Jie Chen, Yan Cheng, Dan Zheng, Shibao Li

Institutions: Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Xuzhou Medical College, Affiliated Hospital of Xuzhou Medical College, Chinese University of Hong Kong

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Jiangsu Commission of Health, National Natural Science Foundation of China, Xuzhou Medical University

OpenAlex ID: W4416850386

Cites: 25

Cited by:

Related to: